Xilio Therapeutics VP and principal accounting officer Edward C. English resigns effective Jan 31, 2023

Xilio Therapeutics, Inc.

Edward C. English notified his resignation as VP, finance, accounting, treasury, and principal accounting officer.
Departure effective January 31, 2023, to pursue other opportunities.
No successor or interim replacement disclosed in the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Edward C. English

vice president, finance, accounting and treasury and principal accounting officer

XLO · Xilio Therapeutics, Inc.

Effective: 2023-01-31
Filed: December 23, 2022, 6:59 PM ET

On December 19, 2022, Edward C. English notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as vice president, finance, accounting and treasury and principal accounting officer of the Company, effective January 31, 2023, to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward C. English resigned as vice president, finance, accounting and treasury and principal accounting officer at Xilio Therapeutics, Inc..

Action: resigned
Role: vice president, finance, accounting and treasury and principal accounting officer

Exact text from the filing

On December 19, 2022, Edward C. English notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as vice president, finance, accounting and treasury and principal accounting officer of the Company, effective January 31, 2023, to pursue other opportunities.

View on SEC.gov

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001544784-22-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.